105 related articles for article (PubMed ID: 10590284)
1. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria.
Andrews JM; Ashby JP; Jevons GM; Wise R
J Antimicrob Chemother; 1999 Dec; 44(6):819-22. PubMed ID: 10590284
[TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O
Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
[TBL] [Abstract][Full Text] [Related]
5. BSAC standardized disc susceptibility testing method (version 7).
Andrews JM;
J Antimicrob Chemother; 2008 Aug; 62(2):256-78. PubMed ID: 18474513
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
Piddock LJ; Jin YF
J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of moxifloxacin against local bacterial isolates.
Ling ML; Tan PL
Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
9. Calculation of composite recovery time: a new pharmacodynamic parameter.
MacKenzie FM; Milne KE; Gould IM
J Antimicrob Chemother; 2002 Aug; 50(2):281-4. PubMed ID: 12161413
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal properties of moxifloxacin and post-antibiotic effect.
Boswell FJ; Andrews JM; Wise R; Dalhoff A
J Antimicrob Chemother; 1999 May; 43 Suppl B():43-9. PubMed ID: 10382875
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
Hoogkamp-Korstanje JA; Roelofs-Willemse J
J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
14. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
Boswell FJ; Andrews JM; Wise R
Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
17. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.
Liebowitz LD; Slabbert M; Huisamen A
J Clin Pathol; 2003 May; 56(5):344-7. PubMed ID: 12719453
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of moxifloxacin(BAY 12-8039) against respiratory tract pathogens from six Latin-American countries.
Cardeñosa G O; Soto-Hernández JL
Chemotherapy; 2000; 46(6):379-82. PubMed ID: 11053902
[TBL] [Abstract][Full Text] [Related]
20. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
